WASHINGTON — There are three FDA-approved drugs for treating alcohol use disorder. But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.
The data, presented this week as an abstract at Digestive Disease Week in D.C., suggest anti-seizure gabapentinoids might be a simple and effective treatment for slowing the progression of alcohol-associated liver disease. Nearly 30 million adults in the United States have alcohol use disorder, according to the 2022 National Survey on Drug Use and Health.
Click this link for the original source of this article.
Author: Isabella Cueto
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.